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Colorectal cancer (CRC) is the fourth most common non-cutaneous malignancy in the United States and the second most frequent
cause of cancer-related death. One of the most important determinants of CRC survival is lymph node metastasis. To determine
whether molecular markers might be prognostic for lymph node metastases, we measured by quantitative real-time RT–PCR the
expression levels of 15 cancer-associated genes in formalin-fixed paraffin-embedded primary tissues derived from stage I–IV CRC
patients with (n¼20) and without (n¼18) nodal metastases. Using the mean of the 15 genes as an internal reference control, we
observed that low expression of b2microglobulin (B2M) was a strong prognostic indicator of lymph node metastases (area under the
curve (AUC)¼0.85; 95% confidence interval (CI)¼0.69–0.94). We also observed that the expression ratio of B2M/Spint2 had the
highest prognostic accuracy (AUC¼0.87; 95% CI¼0.71–0.96) of all potential two-gene combinations. Expression values of Spint2
correlated with the mean of the entire gene set at an R
2 value of 0.97, providing evidence that Spint2 serves not as an independent
prognostic gene, but rather as a reliable reference control gene. These studies are the first to demonstrate a prognostic role of B2M
at the mRNA level and suggest that low B2M expression levels might be useful for identifying patients with lymph node metastasis
and/or poor survival.
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Colorectal cancer (CRC) is the fourth most common noncutaneous
malignancy in the United States and the second most frequent
cause of cancer-related death. In 2007, an estimated 153760 cases
of CRC will be diagnosed, and 52180 people will die from the
disease (Jemal et al, 2006). The most important determinant of
colon cancer survival is stage. The tumour–node–metastasis
system, as defined by the American Joint Committee on Cancer, is
the most commonly used cancer staging system and classifies
colon cancer into four stages based on the depth of invasion of the
bowel wall (T), extent of regional lymph node involvement (N),
and presence of distant sites of metastatic disease (M) (Greene
et al, 2002). Stage I includes T1 and T2 tumours without nodal or
distant metastases and most patients with this disease will be cured
with segmental colectomy alone. The overall 5-year survival (OS)
of this stage is 93.2%. Stage II is subdivided into two classes (IIA
and IIB; OS¼84.7 and 72.2%, respectively) and includes T3 and T4
tumours, respectively. Like stage I, nodal or distant metastasis is
absent in stage II disease. Although many patients with stage II
disease will be cured by surgical resection alone, many patients
with completely resected stage II disease will ultimately die from
colon cancer (Jemal et al, 2006). Stage III disease includes tumours
that do contain nodal disease but do not contain distant
metastases. After complete surgical resection, these patients face
a 50–60% chance of developing recurrent disease. A survival
benefit from adjuvant 5-fluorouracil-based chemotherapy has been
firmly established in these patients, and recent data have
shown further efficacy through the inclusion of oxaliplatin into
adjuvant treatment programmes (Chung and Saltz, 2007; Wolpin
et al, 2007).
At present, the standard procedure for determining the spread
of metastatic disease to lymph nodes is pathological examination
of B20 resected lymph nodes stained with haematoxylin and eosin
(H&E). We reasoned that an assay that was able to identify patients
with metastatic disease by measuring RNA expression levels of
select genes would be helpful for making clinical decisions. In the
current study, we investigated whether expression levels of 14
cancer-associated genes in the primary tumour were correlated
with lymph node metastases. These 14 genes are derived from a set
of 22 that our laboratory has previously identified as being
overexpressed in various cancers (Reed et al, 2007).
In addition to the set of 14 genes, we also chose to examine the
expression of b2microglobulin (B2M). Our rationale for the
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sinclusion of B2M was based on the following observations:
(1) 32% of B2M
null IL-2
null mice develop adenocarcinoma in
the proximal half of the colon between 6 and 12 months (Shah
et al, 1998), (2) out of 19K genes screened from 25 matched CRC
tissue and normal mucosa, B2M was the most highly down-
regulated gene in CRC (Bianchini et al, 2006), (3) oncogenic K-ras
mutations (which are present in the majority of CRC) inhibit the
expression of B2M and other interferon (IFN)-responsive genes
(Klampfer et al, 2003), (4) downregulation of B2M in CRC has been
confirmed by real-time RT–PCR (Bianchini et al, 2006), and (5)
the level of expression of B2M is very high and can be reliably
measured in formalin-fixed paraffin-embedded (FFPE) tissues
(Chen et al, 2007).
MATERIALS AND METHODS
Patients and tissues
This study was approved by the Institutional Review Boards at the
Medical University of South Carolina and by the Mayo Clinic
College of Medicine in Jacksonville. Metastatic and benign lymph
nodes from colon cancer patients. Medical records were searched
for patients who underwent surgical resection and who did (n¼7)
and did not (n¼7) have associated lymph node metastases at the
Mayo Clinic. A 50-mm-thick section was cut for real-time RT–PCR
studies and a 5-mm-thick section was used for H&E staining. The
presence of metastatic disease in lymph nodes identified as
positive was confirmed by the study pathologist. Primary tumour
specimens. Medical records were searched for colon cancer patients
who had at least one metastatic lymph node (n¼20) or no
metastatic lymph nodes (n¼18). Duplicate 50-mm-thick sections
were cut for real-time RT–PCR studies and a 5-mm-thick section
was used for H&E staining.
RNA isolation from paraffin sections
mRNA extraction followed the method of Specht et al (2001).
Briefly, paraffin-embedded tissue sections were deparaffinised
twice with 1ml of xylene at 371C or room temperature for 10min.
The pellet was subsequently washed with 1ml of 100, 90, and 70%
of ethanol and air-dried at room temperature for 2h. The pellet
was resuspended in 200ml of RNA lysis buffer (2% lauryl sulphate,
10mmoll
 1 Tris-HCl (pH 8.0), and 0.1mmoll
 1 EDTA) and
100mg of proteinase K and incubated at 601C for 16h. RNA was
extracted using 1ml of phenol/chloroform (5:1) solution (Sigma,
St Louis, MO, USA). The aqueous layer containing RNA was
transferred to a new 1.5ml tube. Phenol/chloroform extraction was
performed a total of three times. RNA was precipitated with an
equal volume of isopropanol, 0.1 volume of 3moll
 1 sodium
acetate, and 100mg of glycogen at  201C for 16h. After
centrifugation at 12000r.p.m. for 15min (41C), the RNA pellet
was washed with 70% of ethanol and air-dried at room
temperature for 2h. Finally, the pellet was dissolved in 12mlo f
DEPC water and treated with DNase before complementary DNA
(cDNA) synthesis as described in the text.
Complementary DNA synthesis and real-time RT–PCR
Complementary DNA was made from 6ml of RNA described
above, 200U of M-MLV reverse transcriptase (Promega, Madison,
WI, USA), and a panel of truncated gene-specific primers (Table 1).
Real-time RT–PCR was performed on a PE Biosystems
Gene Amp
s 7300 or 7500 Sequence Detection System (Foster
City, CA, USA). With the exception of the SYBR Green I master
mix (purchased from Qiagen, Valencia, CA, USA), all reaction
components were purchased from PE Biosystems. Standard
reaction volume was 10ml and contained 1  SYBR RT–PCR
buffer, 3mM MgCl2, 0.2mM each of dATP, dCTP, and
dGTP, 0.4mM dUTP, 0.1U UNG Erase enzyme, 0.25U AmpliTaq
Gold, 0.35ml cDNA template, and 50nM of oligonucleotide primer.
Initial steps of RT–PCR were 2min at 501C for UNG
Erase activation, followed by a 10min hold at 951C. Cycles
(n¼40) consisted of a 15s melt at 951C, followed by a 1min
annealing/extension at 601C. The final step was a 601C incubation
for 1min. All reactions were performed in triplicate. Before cDNA
synthesis, RNA was treated with or without DNase as described in
the text.
Gene expression and statistical analysis
To quantitate gene expression, the DCt method was used.
As an internal reference, we used either the mean Ct value of all
genes or the median value as described in the text. A primary
tumour sample was considered to have sufficient mRNA
if its mean Ct value was o35.2 (38 out of 38 samples; mean±s.d.
of all samples¼27.5±4.06). Area under the curve (AUC)
measurements were performed for single gene analysis using
MedCalc software (Mariakerke, Belgium); patients were dichot-
omised according to lymph node metastasis status. For AUC
analysis of B2M/gene X expression ratios, DCt values of 14 different
gene combinations were obtained by subtracting the Ct value of
B2M from the other genes. Area under the curve analysis was then
performed using MedCalc software. Associations between catego-
rical values were assessed using Fisher’s exact test. For ordinal
variables (e.g. T-stage, pathologic stage), we also used t-test to
compare mean levels across lymph node and expression categories
due to concern over sparseness. Correlation coefficient analysis of
potential reference genes was performed using Microsoft Excel
software.
Table 1 Primers used for real-time RT–PCR
Gene
Accession
number Sequence 50–30a
Fragment
length
(bp)
AGR2 NM_006408 GCAGAGCAGTTTGTCCTCCTCA 76
GGACATACTGGCCATCAGGAGA
B2M NM_004048 GCCGTGTGAACCATGTGACTTT 97
CCAAATGCGGCATCTTCAAA
CDH1 NM_004360 CCCACCACGTACAAGGGTC 94
CTGGGGTATTGGGGGCATC
CDH3 NM_001793 ATCATCGTGACCGACCAGAAT 166
GGATGGAGTAAGCAACCACCC
CEA6 NM_002483 AGATTGCATGTCCCCTGGAA 104
CATTGAATGGCGTGGATTCA
CK19 NM_002276 AACGGCGAGCTAGAGGTGA 204
TTCCGTCTCAAACTTGGTTCG
Claudin7 NM_001307 TGGCCATCAGATTGTCACAGAC 88
CCAGCCAATAAAGATGGCAGG
Elf3 NM_004433 TCTTCCCCAGCGATGGTTTT 124
TTGCTCTTCTTGCCCTCGA
EpCAM1 NM_002354 CGCAGCTCAGGAAGAATGTG 88
TGAAGTACACTGGCATTGACGA
EpCAM2 NM_002353 ACCCGAGGAGAAGAGGAGTTTG 100
GCTTCTTTCCCAGTGACAAGCA
GPX2 NM_002083 GGACATCAGGAGAACTGTCAGA 150
GTCCTTCAGGTAGGCGAAGAC
MAL2 NM_052886 GTCTGCCTGGAGATTCTGTTCG 103
TCACGGACACAAACATGACCC
MAP7 NM_003980 AGGACAAAGAACGCCACGAA 87
CACGACCAACGGTTATGCTTC
S100P NM_005980 GACGTCTTTCCCGATATTCGG 127
CCACGGCATCCTTGTCTTTTC
Spint2 NM_021102 GTGCCTCAAGAAATGTGCCACT 81
ACAGAGGAATCCGCTGCATTC
RT–PCR¼reverse transcription–PCR.
aGene-specific primer sequences used for
cDNA synthesis are underlined.
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Using a novel microarray/bioinformatics approach, previously we
identified a set of 22 genes that were predicted to be overexpressed
in multiple cancers (Reed et al, 2007). To investigate whether these
genes were overexpressed in metastatic CRC, we selected 14 genes
and measured their level of expression in lymph nodes obtained
from CRC patients who were positive (n¼7) and negative (n¼7)
for metastatic disease by H&E staining. We next performed AUC
analysis, the most commonly used statistical method for determin-
ing accuracies of diagnostic tests (Henderson, 1993). Receiver–
operator characteristic (ROC) curve analysis is based on a plot of
sensitivity as a function of 1 specificity. The area under the ROC
curve (W) is a measure of diagnostic (or prognostic; see below)
accuracy such that values between 0.5 and 0.7 indicate low
accuracy, values between 0.7 and 0.9 indicate moderate accuracy,
and values greater than 0.9 indicate high accuracy (Swets, 1988).
We observed that the AUC values for detection of metastatic
disease of 11 out of 14 (79%) genes were greater than 0.80 (Table 2
and Figure 1). We conclude from this experiment that the set of 14
genes is highly overexpressed in metastatic CRC and hypothesise
that one or more genes in this set may be prognostic for lymph
node metastases.
To determine whether expression levels of molecular markers
might correlate with lymph node metastases, RNA was isolated
from FFPE primary tumour sections as described in Materials
and Methods and analysed for the expression of the 14 cancer-
associated genes listed in Table 1. For reasons stated in the
introduction section, we also included in our marker panel the
B2M gene. Characteristics of the patients with (n¼20) and without
(n¼18) lymph node metastases are shown in Table 3. As
anticipated, we observed a significant association between lymph
node metastases and T-stage, pathologic stage, and tissue
differentiation (continuous).
To evaluate potential prognostic values of the genes, we simply
used as an internal reference the mean Ct value of all 15 genes
(Figure 2). Our rationale for this approach was two-fold. First, an
ideal internal reference gene in cancer prognostics is one that
provides an accurate measure of the amount of tumour and not
tissue. As our genes were selected on the basis of overexpression in
tumour and/or metastatic disease, we reasoned that their mean Ct
value should be a reliable measure of tumour content. Second,
the number of genes we used for reference was 15, a number
sufficiently high to avoid potential problems caused by outliers. In
addition to the analysis using the mean Ct value of the 15-gene set
as an internal reference, a separate analysis was also performed
using the median Ct value.
Using the mean of the entire 15-gene set as an internal reference
control, we calculated DCt values for all genes and performed AUC
analysis. We observed that the only gene whose AUC value was
higher than 0.80 for prognosis of nodal metastases was B2M
(AUC¼0.85, 95% confidence interval (CI)¼0.69–0.94; Table 4),
such that low expression of B2M was associated with nodal
metastases. A similar AUC value (0.83, 95% CI¼0.67–0.93) for
B2M was obtained when the median value was substituted for the
mean (not shown). The gene with the second highest prognostic
accuracy was GPX2 (Table 4); low expression of this gene was also
associated with lymph node metastases.
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Figure 1 Real-time RT–PCR analysis of metastatic and benign lymph
nodes from colon cancer patients. Real-time PCR analyses of seven benign
lymph nodes (left side of each matched data set; open triangles) and seven
metastatic lymph nodes (right side of each matched data set; closed
diamonds) were performed as described in Materials and Methods using
primer pairs for the indicated genes. Ct values for each gene were
determined from triplicate reactions. DCt values were obtained by
subtracting the mean Ct value of B2M (which is highly expressed in normal
lymph node tissue) from the mean Ct value for each respective gene. Note:
The mean B2M Ct value of the metastatic lymph nodes was slightly lower
(i.e. B2M gene expression was slightly higher) but not significantly different
from that of benign tissue (17.8±2.1 vs 20.2±2.1, respectively).
B
2
M
C
K
1
9
E
L
F
3
C
D
H
3
S
1
0
0
P
C
D
H
1
M
A
L
2
E
p
C
A
M
1
S
p
i
n
t
2
E
p
C
A
M
2
C
l
a
u
d
i
n
7
G
P
X
2
X
A
G
C
E
A
6
M
a
p
7
10
5
–5
0
–10
∆
C
t
Genes
Figure 2 Real-time PCR analyses of FFPE primary tissue from CRC
patients. Real-time RT–PCR was performed on patients who did (n¼18;
right side of each matched data set; filled circles) and who did not have
(n¼18; left side of each matched data set; open circles) metastatic lymph
nodes from CRC as described in Materials and Methods using primer pairs
for the indicated genes. Ct values for each gene were determined from
triplicate reactions.
Table 2 Diagnostic accuracies of cancer-associated genes for detection
of metastatic disease in lymph nodes derived from CRC patients
Gene AUC 95% CI
Map7 0.980 0.734–1.000
AGR2 0.939 0.674–0.987
MAL2 0.939 0.674–0.987
EpCAM2 0.939 0.674–0.987
EpCAM1 0.939 0.674–0.987
CEA6 0.918 0.647–0.988
CDH1 0.918 0.647–0.988
S100P 0.837 0.548–0.972
ELF3 0.837 0.548–0.972
Sprint2 0.816 0.525–0.964
Claudin7 0.816 0.525–0.964
GPX2 0.714 0.419–0.914
CDH3 0.694 0.399–0.903
CK19 0.531 0.255–0.792
AUC¼area under the curve; CRC¼colorectal cancer; CI¼confidence interval.
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DCt¼Ctmean 15-gene set CtB2M), we observed that the sensitivity for
nodal disease detection was 85% (17 out of 20 stage III and stage IV
patients were correctly classified; see Table 3), whereas the specificity
was 83% (15 out of 18 stage I and stage II patients were correctly
classified; see Table 3). Interestingly, all apparent ‘false positives’ in
the node-negative groups were derived from stage I patients. The
relevance of this finding is discussed in further detail below.
To investigate whether one or two genes from the panel could
substitute for the entire set, we analysed our expression results in
two manners. First, we calculated the expression ratios of all B2M/
gene X pairs to determine whether a particular pair exhibited high
prognostic accuracy. These calculations revealed that the expres-
sion ratio of B2M/Spint2 had the highest prognostic accuracy of
all possible pairs (AUC¼0.87; 95% CI¼0.71–0.96). Second, we
performed a correlation coefficient analysis and determined that
the mean Ct value of the 15-gene set was most highly correlated
with Spint2 (R
2¼0.97; Figure 3). The results of these analyses
suggest that Spint2 can be used as an internal reference
control gene.
To assess the reproducibility of the B2M/Spint2 expression
ratio, the analysis described above was repeated using duplicate
tissue sections and RNA that was treated with DNase. In
this second analysis, we measured the expression values of
B2M, Spint2, GPX2, Elf3, CDH1, CDH3, EpCAM1, and CEA6.
We observed that the prognostic accuracy of the Spint2/B2M
expression ratio as determined by AUC analysis was within 6%
of the value observed in the first study (AUC¼0.91; 95%
CI¼0.73–0.98; data not shown). These results provide evidence
that the B2M/Spint2 expression ratio is a reliable indicator of
nodal metastases in CRC patients. Further, using the eight genes
as internal reference, we observed that the prognostic accuracy
of B2M was 0.82 (95% CI¼0.63–0.94; data not shown).
In a separate study conducted with a small set of tissues
(n¼14), we observed that B2M maintained its high prognostic
accuracy for lymph node metastases (AUC¼0.79) when
more classical reference control genes TBP (Ohl et al, 2006)
or UBP (Andersen et al, 2004) were substituted for Spint2
(not shown).
Table 3 Patient information
Variable Categories LN+ P-value
Low expression
of B2M
a P-value
Gender Male 12/20 (60%) 0.52 14/20 (70%) 0.03
Female 8/18 (44%) 6/18 (33%)
Site Right colon 11/24 (46%) 0.63 11/24 (46%) 0.63
Left colon 2/2 (100%) 2/2 (100%)
Rectum 4/7 (57%) 4/7 (57%)
Sigmoid 2/3 (67%) 2/3 (67%)
Left colon+rectum 1/1 (100%) 1/1 (100%)
transverse 0/1 (0%) 0/1 (0%)
Type Adeno 15/30 (50%) 0.70 17/30 0.44
Adeno, mucinous 5/8 (63%) 3/8
Differentiation Well 3/10 (30%) 0.13 6/10 (60%) 0.82
Well to moderate 0/1 (0%) 0/1 (0%)
Moderate 14/24 (58%) 13/24 (54%)
Moderate to poor 2/2 (100%) 1/2 (50%)
Poor 1/1 (100%) 0/1 (0%)
Continuous 0.03 0.52
T-stage 1 0/2 (0%) 0.001 0/2 (0%) 0.20
2 2/12 (17%) 5/12 (42%)
3 17/23 (74%) 14/23 (61%)
4 1/1 (100%) 1/1 (100%)
Continuous o0.001 0.05
Path stage I 0/12 (0%) o0.001 3/12 (25%) o0.001
IIA 0/6 (0%) 0/6 (0%)
IIIA 5/5 (100%) 3/5 (60%)
IIIB 2/2 (100%) 2/2 (100%)
IIIC 7/7 (100%) 6/7 (86%)
IV 6/6 (100%) 6/6 (100%)
LN+¼lymph node positive.
aLow B2M-expressing sample was defined by Ctmean 15-gene set CtB2M44.5.
Table 4 Prognostic accuracies of single genes for lymph node metastases
using the 15-gene set as an internal reference
Gene AUC
a 95% CI
B2M 0.846 0.692–0.942
GPX2 0.792 0.629–0.906
Claudin7 0.717 0.547–0.850
S100P 0.669 0.498–0.813
AGR2 0.665 0.494–0.810
Map7 0.653 0.481–0.799
EpCAM1 0.650 0.478–0.797
CK19 0.647 0.476–0.795
CDH1 0.632 0.460–0.782
CDH3 0.606 0.434–0.760
EpCAM2 0.601 0.430–0.756
MAL2 0.565 0.395–0.725
ELF3 0.565 0.395–0.725
Sprint2 0.546 0.377–0.708
CEA6 0.528 0.360–0.691
AUC¼area under the curve; CI¼confidence interval.
aArea under the curve values
were obtained using the mean Ct value of the patient sample as an internal reference.
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In this study, we observed that low expression of B2M was a strong
prognostic indicator of lymph node metastases regardless of
whether the mean expression value of the 15-gene set was used as
an internal reference control (AUC¼0.85; Table 4), the median
expression value of the 15-gene set was used (AUC¼0.83), Spint2
was used as a single internal reference gene (AUC¼0.87), or
classic reference genes such as TBP or UBP were used
(AUC¼0.79). Based on the results described in this study, the
mean (±s.d.) accuracy of B2M for prognosis of lymph node
metastases was 0.83±0.04, a value that is sufficiently high to
warrant further investigation into this biomarker. Although a
previous study has shown that B2M was the most highly
downregulated gene in CRC compared to adjacent normal tissue
(Bianchini et al, 2006), this is the first study to show a relationship
between B2M mRNA levels and a clinical parameter related to
outcome of CRC patients.
B2M is known as a classic IFN-responsive gene (Yan et al, 2004;
Gottenberg et al, 2006; Gray et al, 2006; Joyce et al, 2007; Scherbik
et al, 2007; Urosevic et al, 2007). Interferons were originally
discovered as antiviral proteins that inhibit virus replication
(Isaacs and Lindenmann, 1987). Upon virus infection, IFNs are
induced in mammalian cells and thus mediate cellular homeostatic
responses to virus infection. In addition to their antiviral
properties, IFNs are involved in many other physiological
processes including cell growth and proliferation, cell death, the
immune response, and other cellular defence mechanisms (Sen,
2001). In colon cancer, oncogenic K-ras inhibits the expression of
IFN-responsive genes through inhibition of STAT1 and STAT2
expression (Klampfer et al, 2003). Under normal circumstances,
IFN induces phosphorylation of STAT1, which is released from the
IFNg receptor and forms STAT1 homodimers. The homodimers
then translocate to the nucleus to activate target genes (Darnell
et al, 1994; Ihle and Kerr, 1995) such as B2M.
In addition to inactivation by K-ras mutations in colon cancer,
B2M gene expression can also be impaired by mutations in the
coding and non-coding (promoter) regions. For example, in HCT-
15 colon cancer cells, both B2M alleles are mutated, one by an 11
base-pair deletion and the other by a point mutation, resulting in
the loss of HLA class 1 surface antigens (Gattoni-Celli et al, 1992).
Loss of B2M mRNA expression has important implications at the
protein level. B2M is a chaperone of major histocompatibility
complex (MHC) class I (-like) molecules that play a central role in
antigen presentation, immunoglobulin transport, and iron meta-
bolism. In the tumour host immune response, HLA-A,B,C
assembles with B2M in the endoplasmic reticulum (Momburg
and Koch, 1989; Momburg et al, 1989). Loss of these class 1
antigens is associated with decreased histological differentiation
in colon cancer (Gattoni-Celli et al, 1992), as well as increased
malignancy in a number of neoplasms, including B-cell lymphoma
(Moller et al, 1987) and melanoma (Paschen et al, 2003).
Interestingly, loss of the native HLA-A,B,C/B2M complex appears
to be sporadic in nature; in some cases, the loss is localised to
certain portions of the tumour, whereas in others, loss of B2M is
evident across the entire tumour (Momburg and Koch, 1989). As
MHC class 1 antigens are required for the host to mount a tumour
response, the loss of these antigens allows a tumour to escape
recognition by the immune system.
Despite the known biological properties of B2M, this gene has
been inadvertently used as an internal reference control in studies
involving IFN signalling (Einav et al, 2005; Tamassia et al, 2007), as
well as real-time PCR studies of colon cancer prognosis (Takeuchi
et al, 2003). Interestingly, in the study performed by Takeuchi
et al, the investigators examined 36 tumours and observed that the
mRNA copy numbers of B2M in T3/T4 cases (mean 1.78 10
5
copies) had a tendency to be lower than that in T1/T2 cases (mean
4.44 10
5 copies; P¼0.16), but were not highly correlated
with another reference gene. Owing to the later observation, the
authors correctly concluded that B2M should not be used as an
internal reference control. However, the investigators failed to
recognise that the B2M gene itself might serve as a prognostic
marker.
In this study, we observed that Spint2 was a reliable internal
reference control gene for CRC. This result is consistent with the
study of Kataoka et al (2000), who found no relationship between
Spint2 mRNA and tumour stages in CRC. Further, during the
course of acetic acid-induced experimental colitis in an in vivo
mouse model, Spint1 but not Spint2 was upregulated in the
recovery phase (Itoh et al, 2000), a process that requires cellular
regeneration. This result further supports the concept that mRNA
expression levels of Spint2 may remain constant during tumour
progression in CRC.
Spint1 and Spint2 are Kunitz-type serine protease inhibitors that
regulate hepatocyte growth factor (HGF) activity through inhibi-
tion of HGF activator (HGFA), matriptase and hepsin (Parr and
Jiang, 2006). Matriptase, urokinase-type activator, HGFA, and
hepsin are the main factors responsible for converting inactive
pro-HGF into active HGF, which is mainly secreted by stromal
fibroblasts. Hepatocyte growth factor is known to play a number of
roles in cancer metastasis and tumour growth. Thus, because Spint1
and Spint2 serve to inhibit the activity of HGF, these genes have
been characterised as tumour suppressors (Morris et al, 2005).
Further, in a study of 41 ovarian cancer patients, low expression of
Spint2 was determined to be an independent factor of poor
prognosis (P¼0.013; hazard ratio, 2.30; Tanaka et al, 2003).
Interestingly, the suppression of metastatic behaviour (e.g. cell
motility) by Spint2 can be abrogated in vitro by treatment with
extracellular signal-regulated kinase/mitogen-activated protein
kinase and phospholipase C-g inhibitors (Morris et al, 2005),
suggesting that the suppressive effects of this gene can be bypassed.
Of the 14 cancer-associated genes used in the current
study, none proved to be prognostic for lymph node metastases
at an AUC value 40.80. This was rather surprising, as several of
these genes have been previously shown to be prognostic for
various cancers. For example, immunohistochemical studies have
shown that low expression of E-Cadherin is associated with
poor survival in a number of cancers including pancreatic
(Shimamura et al, 2003), thyroid (Scheumman et al, 1995), gall
bladder (Hirata et al, 2006), breast (Park et al, 2007), lung (Nozawa
et al, 2006), hepatic (Wu et al, 2006), endometrial (Scholten et al,
2006), and colon (Pena et al, 2005) cancer. Further, we were also
surprised to find that EpCAM2/TROP2 was not a prognostic
factor, as overexpression of this gene has been shown to be
associated with liver metastases and survival in CRC patients
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Figure 3 Spint2 expression levels are highly correlated with the mean of
the 15-gene set. Mean Ct values of the 15 genes were obtained by dividing
the sum of the Ct values by 15. In cases where no signal was detected, a Ct
value of 40 was used. Linear regression analysis of the indicated data points
was performed using Microsoft Excel software.
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s(Ohmachi et al, 2006). It is not clear why we failed to observe a
prognostic role for EpCAM2. In contrast to all other genes used in
this study, EpCAM2 arose from retrotransposition (of EpCAM1)
and does not contain introns. Hence, in the absence of DNase
treatment, amplification of this gene is prone to genomic
contamination.
A long-range goal of our research group is to develop a
prognostic assay that can be used to predict what stage II
colon cancer patients might benefit from adjuvant chemotherapy.
In this study, we observed that 3 out of 18 patients who were
node negative by pathological assessment had low levels of B2M.
The clinical significance of this finding is not known. However,
in a subsequent study performed on untreated stage II tissues
obtained from a separate institute, we discovered that low
B2M expression was an independent prognostic marker for poor
patient survival (Blum et al, 2008). Thus, the results described
here may ultimately prove to be of benefit to a significant number
of CRC patients.
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